REFERENCES
1. Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9:880.
2. Amaya-Amaya J, Rojas-Villarraga A, Mantilla RD, et al. Rheumatoid arthritis. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside. Bogota (Colombia): El Rosario University Press; 2013. Chapter 24.
3. Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid arthritis: a brief overview of the treatment. Med Princ Pract. 2018;27:501-7.
5. Ben Mrid R, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-rheumatoid drugs advancements: new insights into the molecular treatment of rheumatoid arthritis. Biomed Pharmacother. 2022;151:113126.
6. Haschka J, Englbrecht M, Huebe A, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75:45-51.
7. Frazzei G, Musters A, de Vries N, Tas SW, van Vollenhoven RF. Prevention of rheumatoid arthritis: a systematic literature review of preventive strategies in at-risk individuals. Autoimmun Rev. 2023;22:103217.
8. Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844.
9. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15-29.
10. Khader Y, Beran A, Ghazaleh S, Lee-Smith W, Altorok N. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022;41:3615-27.
11. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017;9:249-62.
12. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010;36:213-41.
13. Sokolova MV, Schett G, Steffen U. Autoantibodies in rheumatoid arthritis: historical background and novel findings. Clin Rev Allergy Immunol. 2022;63:138-51.
14. Holers VM, Demoruelle KM, Buckner JH, et al. Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis. Nat Rev Rheumatol. 2024;20:601-13.
15. Sanmartí R, Frade-Sosa B, Ponce A. The so-called pre-clinical rheumatoid arthritis: doubts, challenges, and opportunities. J Clin Med. 2024;13:6387.
16. Jiao Y, Wu L, Huntington ND, Zhang X. Crosstalk between gut microbiota and innate immunity and its implication in autoimmune diseases. Front Immunol. 2020;11:282.
17. De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019;195:74-85.
18. Lin L, Zhang K, Xiong Q, et al. Gut microbiota in pre-clinical rheumatoid arthritis: From pathogenesis to preventing progression. J Autoimmun. 2023;141:103001.
19. Fan J, Jiang T, He D. Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Front Immunol. 2023;14:1189036.
20. Wells PM, Williams FMK, Matey-Hernandez ML, Menni C, Steves CJ. 'RA and the microbiome: do host genetic factors provide the link? J Autoimmun 2019;99:104-15.
21. Malczewski AB, Coward JI, Ketheesan N, Navarro S. Immunometabolism: the role of gut-derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy. Clin Transl Med. 2025;15:e70472.
22. Romero-Figueroa MDS, Ramírez-Durán N, Montiel-Jarquín AJ, Horta-Baas G. Gut-joint axis: gut dysbiosis can contribute to the onset of rheumatoid arthritis via multiple pathways. Front Cell Infect Microbiol. 2023;13:1092118.
23. Longo UG, Lalli A, Bandini B, et al. Role of the gut microbiota in osteoarthritis, rheumatoid arthritis, and spondylarthritis: an update on the gut-joint axis. Int J Mol Sci. 2024;25:3242.
24. Arya P, Sharma V, Singh P, Thapliyal S, Sharma M. Bacterial endotoxin-lipopolysaccharide role in inflammatory diseases: an overview. Iran J Basic Med Sci. 2025;28:553-64.
25. Farhana A, Khan YS. Biochemistry, Lipopolysaccharide. [Updated 2023 Apr 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available online: https://www.ncbi.nlm.nih.gov/books/NBK554414/. [Last accessed 24 February 2026].
26. An L, Wirth U, Koch D, et al. The Role of Gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases. J Gastrointest Surg. 2022;26:671-83.
27. Lin TL, Shu CC, Chen YM, et al. Like cures like: pharmacological activity of anti-inflammatory lipopolysaccharides from gut microbiome. Front Pharmacol. 2020;11:554.
28. Mahroum N, Seida R, Shoenfeld Y. Triggers and regulation: the gut microbiome in rheumatoid arthritis. Expert Rev Clin Immunol. 2023;19:1449-56.
29. Reyes-Castillo Z, Valdés-Miramontes E, Llamas-Covarrubias M, Muñoz-Valle JF. Troublesome friends within us: the role of gut microbiota on rheumatoid arthritis etiopathogenesis and its clinical and therapeutic relevance. Clin Exp Med. 2021;21:1-13.
30. Balasundaram D, Veerasamy V, Sylvia Singarayar M, Neethirajan V, Ananth Devanesan A, Thilagar S. Therapeutic potential of probiotics in gut microbial homeostasis and Rheumatoid arthritis. Int Immunopharmacol. 2024;137:112501.
31. Greenblatt HK, Kim HA, Bettner LF, Deane KD. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Opin Rheumatol. 2020;32:289-96.
32. Romão VC, Fonseca JE. Disease mechanisms in preclinical rheumatoid arthritis: a narrative review. Front Med (Lausanne). 2022;9:689711.
33. Cope AP, Jasenecova M, Vasconcelos JC, et al.; APIPPRA study investigators. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838-49.
34. Tsetseri MN, Silman AJ, Keene DJ, Dakin SG. The role of the microbiome in rheumatoid arthritis: a review. Rheumatol Adv Pract. 2023;7:rkad034.
35. Coradduzza D, Bo M, Congiargiu A, et al. Decoding the microbiome’s influence on rheumatoid arthritis. Microorganisms. 2023;11:2170.
36. Alpízar-Rodríguez D, Finckh A, Gilbert B. The role of nutritional factors and intestinal microbiota in rheumatoid arthritis development. Nutrients. 2020;13:96.
37. Nii T, Maeda Y, Motooka D, et al. Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis. Ann Rheum Dis. 2023;82:621-9.
38. Rooney CM, Mankia K, Emery P. The role of the microbiome in driving RA-related autoimmunity. Front Cell Dev Biol. 2020;8:538130.
39. Poznyak AV, Kashirskikh DA, Postnov AY, Popov MA, Sukhorukov VN, Orekhov AN. Sialic acid as the potential link between lipid metabolism and inflammation in the pathogenesis of atherosclerosis. Braz J Med Biol Res. 2023;56:e12972.
40. Maeda Y, Takeda K. Host-microbiota interactions in rheumatoid arthritis. Exp Mol Med. 2019;51:1-6.
41. Koh JH, Lee EH, Cha KH, Pan CH, Kim D, Kim WU. Factors associated with the composition of the gut microbiome in patients with established rheumatoid arthritis and its value for predicting treatment responses. Arthritis Res Ther. 2023;25:32.
42. Rogier R, Ederveen THA, Boekhorst J, et al. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis. Microbiome. 2017;5:63.
43. Pianta A, Arvikar S, Strle K, et al. Evidence of the immune relevance of Prevotella copri, a gut microbe, in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;69:964-75.
44. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30:492-506.
45. Seifert JA, Bemis EA, Ramsden K, et al. Association of antibodies to Prevotella copri in anti-cyclic citrullinated peptide-positive individuals at risk of developing rheumatoid arthritis and in patients with early or established rheumatoid arthritis. Arthritis Rheumatol. 2023;75:507-16.
46. Wei F, Zhao M, Sun X, Ma H, Yin H, Shen X. Causal associations between gut microbiota and rheumatoid arthritis: a two-sample Mendelian randomization study. Medicine (Baltimore). 2025;104:e42596.
47. Horta-Baas G, Romero-Figueroa MDS, Montiel-Jarquín AJ, Pizano-Zárate ML, García-Mena J, Ramírez-Durán N. Intestinal dysbiosis and rheumatoid arthritis: a link between gut microbiota and the pathogenesis of rheumatoid arthritis. J Immunol Res. 2017;2017:4835189.
48. Zhao T, Wei Y, Zhu Y, et al. Gut microbiota and rheumatoid arthritis: from pathogenesis to novel therapeutic opportunities. Front Immunol. 2022;13:1007165.
49. Marietta EV, Murray JA, Luckey DH, et al. Suppression of inflammatory arthritis by human gut-derived Prevotella histicola in humanized mice. Arthritis Rheumatol. 2016;68:2878-88.
50. Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017;151:363-74.
51. Balakrishnan B, Luckey D, Bodhke R, et al. Prevotella histicola protects from arthritis by expansion of allobaculum and augmenting butyrate production in humanized mice. Front Immunol. 2021;12:609644.
52. Zang X, Xiao M, Yu L, et al. Prevotella copri - a potential next-generation probiotic. Food Frontiers. 2024;5:1391-409.
53. Hayase E, Jenq RR. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med. 2021;13:107.
54. Rooney CM, Jeffery IB, Mankia K, Wilcox MH, Emery P. Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study. Ann Rheum Dis. 2024;84:562-74.
55. Roszyk E, Puszczewicz M. Role of human microbiome and selected bacterial infections in the pathogenesis of rheumatoid arthritis. Reumatologia. 2017;55:242-50.
56. Zhao Q, Chen Y, Huang W, Zhou H, Zhang W. Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduct Target Ther. 2023;8:386.
57. Zádori ZS, Király K, Al-Khrasani M, Gyires K. Interactions between NSAIDs, opioids and the gut microbiota - future perspectives in the management of inflammation and pain. Pharmacol Ther. 2023;241:108327.
58. Hao Y. Gut microbiota-immune axis in the regulation of rheumatoid arthritis: from mechanism to precision probiotic strategies. Mod Rheumatol. 2025;36:1-14.
59. Hellwig M, Diel P, Eisenbrand G, et al. Dietary glycation compounds - implications for human health. Crit Rev Toxicol. 2024;54:485-617.
60. Phuong-Nguyen K, McNeill BA, Aston-Mourney K, Rivera LR. Advanced glycation end-products and their effects on gut health. Nutrients. 2023;15:405.
61. Shoham S, Pintel N, Avni D. Oxidative stress, gut bacteria, and microalgae: a holistic approach to manage inflammatory bowel diseases. Antioxidants (Basel). 2025;14:697.
62. Ma Z, Zuo T, Frey N, Rangrez AY. A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation. Signal Transduct Target Ther. 2024;9:237.
63. Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, Chang MW. Microbiome and human health: current understanding, engineering, and enabling technologies. Chem Rev. 2023;123:31-72.
64. Wu IW, Lin CY, Chang LC, et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: discovery and validation study. Int J Biol Sci. 2020;16:420-34.
65. You Y, Xiang T, Yang C, et al. Interactions between the gut microbiota and immune cell dynamics: novel insights into the gut-bone axis. Gut Microbes. 2025;17:2545417.
66. Ortega MA, Álvarez-Mon MA, García-Montero C, et al. Microbiota-gut-brain axis mechanisms in the complex network of bipolar disorders: potential clinical implications and translational opportunities. Mol Psychiatry. 2023;28:2645-73.
67. Xie X, Chen X, Wang X, Wang S, Qi P. Dual regulatory effects of gut microbiota and their metabolites in rheumatoid arthritis: balancing pathogenic and protective mechanisms. Front Immunol. 2025;16:1584023.
68. Gargari G, Mantegazza G, Cremon C, et al. Collinsella aerofaciens as a predictive marker of response to probiotic treatment in non-constipated irritable bowel syndrome. Gut Microbes. 2024;16:2298246.
69. Chen J, Wright K, Davis JM, et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8:43.
70. Korzeniowska A, Bryl E. Infectious and commensal bacteria in rheumatoid arthritis-role in the outset and progression of the disease. Int J Mol Sci. 2024;25:3386.
71. Romano S, Wirbel J, Ansorge R, et al. Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson’s disease. Nat Commun. 2025;16:4227.
72. Vandeputte D, Kathagen G, D’hoe K, et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature. 2017;551:507-11.
73. Knight R, Vrbanac A, Taylor BC, et al. Best practices for analysing microbiomes. Nat Rev Microbiol. 2018;16:410-22.
74. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome Datasets are compositional: and this is not optional. Front Microbiol. 2017;8:2224.
75. Juárez-Chairez MF, Cid-Gallegos MS, Jiménez-Martínez C, Prieto-Contreras LF, Bollain-Y-Goytia de-la-Rosa JJ. The role of microbiota on rheumatoid arthritis onset. Int J Rheum Dis. 2024;27:e15122.
76. Wagner S, Weber M, Paul LS, et al. Absolute abundance calculation enhances the significance of microbiome data in antibiotic treatment studies. Front Microbiol. 2025;16:1481197.
77. Guo C, Che X, Briese T, et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host Microbe. 2023;31:288-304.e8.
78. Liu Z, Wu Y, Luo Y, et al. Self-balance of intestinal flora in spouses of patients with rheumatoid arthritis. Front Med (Lausanne). 2020;7:538.
79. Sadeghpour Heravi, F. Gut microbiota and autoimmune diseases: mechanisms, treatment, challenges, and future recommendations. Curr Clin Micro Rpt. 2024;11:18-33.
80. Jeong JJ, Park HJ, Cha MG, et al. The lactobacillus as a probiotic: focusing on liver diseases. Microorganisms. 2022;10:288.
81. Chen JF, Ou-Yang MC, Hsia KC, et al. A three-arm, randomized, double-blind, placebo-controlled study to evaluate the safety of Lactobacillus salivarius AP-32 and Bifidobacterium animalis CP-9 used individually in healthy infants. Nutrients. 2023;15:3426.
82. Yang Y, Hong Q, Zhang X, Liu Z. Rheumatoid arthritis and the intestinal microbiome: probiotics as a potential therapy. Front Immunol. 2024;15:1331486.
83. Esvaran M, Conway PL. Lactobacillus fermentum PC1 has the capacity to attenuate joint inflammation in collagen-induced arthritis in DBA/1 mice. Nutrients. 2019;11:785.
84. Paul AK, Paul A, Jahan R, et al. Probiotics and amelioration of rheumatoid arthritis: significant roles of Lactobacillus casei and Lactobacillus acidophilus. Microorganisms. 2021;9:1070.
85. Fan Z, Ross RP, Stanton C, et al. Lactobacillus casei CCFM1074 alleviates collagen-induced arthritis in rats via balancing Treg/Th17 and modulating the metabolites and gut microbiota. Front Immunol. 2021;12:680073.
86. Ferro M, Charneca S, Dourado E, Guerreiro CS, Fonseca JE. Probiotic supplementation for rheumatoid arthritis: a promising adjuvant therapy in the gut microbiome era. Front Pharmacol. 2021;12:711788.
87. Bungau SG, Behl T, Singh A, et al. Targeting probiotics in rheumatoid arthritis. Nutrients. 2021;13:3376.
88. Rahman SO, Bariguian F, Mobasheri A. The potential role of probiotics in the management of osteoarthritis pain: current status and future prospects. Curr Rheumatol Rep. 2023;25:307-26.
89. Thomas S, Izard J, Walsh E, et al. The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists. Cancer Res. 2017;77:1783-812.
90. Godha Y, Kumar S, Wanjari A. Role of gut microbiota in the development and management of rheumatoid arthritis: a narrative review. Cureus. 2023;15:e49458.
91. Orekhov AN, Summerhill VI, Khotina VA, Popov MA, Uzokov JK, Sukhorukov VN. Role of mitochondria in the chronification of inflammation: focus on dysfunctional mitophagy and mitochondrial DNA mutations. Gene Expr. 2023;22:329-44.
92. Lukas C, Mary J, Debandt M, et al. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. Arthritis Res Ther. 2019;21:243.
93. Heydari-Kamjani M, Demory Beckler M, Kesselman MM. Reconsidering the use of minocycline in the preliminary treatment regime of rheumatoid arthritis. Cureus. 2019;11:e5351.
94. Smith CJ, Sayles H, Mikuls TR, Michaud K. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. Arthritis Res Ther. 2011;13:R168.
95. Nayak RR. Fanning the flames of autoimmunity: the microbiome in rheumatic disease. Arthritis Rheumatol. 2022;74:549-52.
96. Cusumano G, Flores GA, Venanzoni R, Angelini P. The impact of antibiotic therapy on intestinal microbiota: dysbiosis, antibiotic resistance, and restoration strategies. Antibiotics (Basel). 2025;14:371.
97. Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020;110:102400.
98. Xu H, Zhao H, Fan D, et al. Interactions between gut microbiota and immunomodulatory cells in rheumatoid arthritis. Mediators Inflamm. 2020;2020:1430605.
99. Koester ST, Chow A, Pepper-Tunick E, et al. Familial clustering of dysbiotic oral and fecal microbiomes in juvenile dermatomyositis. Sci Rep. 2024;14:16158.
100. Berthelot JM, Bandiaky ON, Le Goff B, et al. Another look at the contribution of oral microbiota to the pathogenesis of rheumatoid arthritis: a narrative review. Microorganisms. 2021;10:59.
101. Danckert NP, Freidin MB, Granville Smith I, et al. Treatment response in rheumatoid arthritis is predicted by the microbiome: a large observational study in UK DMARD-naive patients. Rheumatology (Oxford). 2024;63:3486-95.
102. Volkova A, Ruggles KV. Predictive metagenomic analysis of autoimmune disease identifies robust autoimmunity and disease specific microbial signatures. Front Microbiol. 2021;12:621310.
103. Peters BA, Wilson M, Moran U, et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 2019;11:61.
104. Nayak RR, Alexander M, Deshpande I, et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host Microbe. 2021;29:362-377.e11.
105. Chen YC, Hou CY, Hsu MH, Huang LT, Hsiao CC, Sheen JM. The impact of gut microbiota changes on methotrexate-induced neurotoxicity in developing young rats. Biomedicines. 2024;12:908.
106. Letertre MPM, Munjoma N, Wolfer K, et al. A two-way interaction between methotrexate and the gut microbiota of male Sprague-Dawley rats. J Proteome Res. 2020;19:3326-39.
107. Crouwel F, Buiter HJC, de Boer NK. Gut microbiota-driven drug metabolism in inflammatory bowel disease. J Crohns Colitis. 2021;15:307-15.
108. Lima SF, Pires S, Rupert A, et al. The gut microbiome regulates the clinical efficacy of sulfasalazine therapy for IBD-associated spondyloarthritis. Cell Rep Med. 2024;5:101431.
109. Wang X, Peng J, Cai P, et al. The emerging role of the gut microbiota and its application in inflammatory bowel disease. Biomed Pharmacother. 2024;179:117302.
110. McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold GL. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther. 2018;47:26-42.
111. Zaragoza-García O, Castro-Alarcón N, Pérez-Rubio G, Guzmán-Guzmán IP. DMARDs-gut microbiota feedback: implications in the response to therapy. Biomolecules. 2020;10:1479.
112. Zhang L, Chu CQ. Gut microbiota-medication interaction in rheumatic diseases. Front Immunol. 2021;12:796865.
113. Bodkhe R, Balakrishnan B, Taneja V. The role of microbiome in rheumatoid arthritis treatment. Ther Adv Musculoskelet Dis. 2019;11:1759720X19844632.
114. Cohen I, Ruff WE, Longbrake EE. Influence of immunomodulatory drugs on the gut microbiota. Transl Res. 2021;233:144-61.
115. Mei L, Yang Z, Zhang X, et al. Sustained drug treatment alters the gut microbiota in rheumatoid arthritis. Front Immunol. 2021;12:704089.
116. Gianchecchi E, Fierabracci A. Recent advances on microbiota involvement in the pathogenesis of autoimmunity. Int J Mol Sci. 2019;20:283.
117. Peng J, Lu X, Xie K, et al. Dynamic alterations in the gut microbiota of collagen-induced arthritis rats following the prolonged administration of total glucosides of paeony. Front Cell Infect Microbiol. 2019;9:204.
118. Yurtseven B, Aydemir E, Ayaz F. The role of intestinal microbiota and immune system interactions in autoimmune diseases. Immunotargets Ther. 2025;14:1347-72.
119. Bhattacharjee P, Karim KA, Khan Z. Harnessing the microbiome: a comprehensive review on advancing therapeutic strategies for rheumatic diseases. Cureus. 2023;15:e50964.
120. Oliveira SR, de Arruda JAA, Corrêa JD, et al. Methotrexate and non-surgical periodontal treatment change the oral-gut microbiota in rheumatoid arthritis: a prospective cohort study. Microorganisms. 2023;12:68.
121. Anand N, Gorantla VR, Chidambaram SB. The role of gut dysbiosis in the pathophysiology of neuropsychiatric disorders. Cells. 2022;12:54.
122. Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7:135.
123. Sanchez P, Letarouilly JG, Nguyen Y, et al. Efficacy of probiotics in rheumatoid arthritis and spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14:354.
124. Kazemi A, Soltani S, Ghorabi S, et al. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2020;39:789-819.
125. Li W, Zhang Y, Guo D, Gong R, Yuan J, Yang H. Quality of evidence supporting the role of probiotics for rheumatoid arthritis: an overview of systematic reviews. Front Immunol. 2024;15:1397716.
126. Feng J, Pan C, Gou Y, et al. EAT-lancet diet modifies the risk of rheumatoid arthritis through metabolomic signature. Arthritis Rheumatol. 2026;78:68-79.
127. Zhang W, Mackay CR, Gershwin ME. Immunomodulatory effects of microbiota-derived short-chain fatty acids in autoimmune liver diseases. J Immunol. 2023;210:1629-39.
128. Liu XF, Shao JH, Liao YT, et al. Regulation of short-chain fatty acids in the immune system. Front Immunol. 2023;14:1186892.
129. Schlatterer K, Peschel A, Kretschmer D. Short-chain fatty acid and FFAR2 activation - a new option for treating infections? Front Cell Infect Microbiol 2021;11:785833.
130. Chun E, Lavoie S, Fonseca-Pereira D, et al. Metabolite-sensing receptor Ffar2 regulates colonic group 3 innate lymphoid cells and gut immunity. Immunity. 2019;51:871-884.e6.
131. Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut Microbes. 2021;13:1-24.
132. Fusco W, Lorenzo MB, Cintoni M, et al. Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. 2023;15:2211.
133. Tomé-Carneiro J, Visioli F. Plant-based diets reduce blood pressure: a systematic review of recent evidence. Curr Hypertens Rep. 2023;25:127-50.
134. Baroni L, Rizzo G, Galchenko AV, Zavoli M, Serventi L, Battino M. Health benefits of vegetarian diets: an insight into the main topics. Foods. 2024;13:2398.
135. Pohl A, Schünemann F, Bersiner K, Gehlert S. The impact of vegan and vegetarian diets on physical performance and molecular signaling in skeletal muscle. Nutrients. 2021;13:3884.
136. Direito R, Rocha J, Sepodes B, Eduardo-Figueira M. Phenolic compounds impact on rheumatoid arthritis, inflammatory bowel disease and microbiota modulation. Pharmaceutics. 2021;13:145.
137. Gál R, Halmosi R, Gallyas F Jr, et al. Resveratrol and beyond: the effect of natural polyphenols on the cardiovascular system: a narrative review. Biomedicines. 2023;11:2888.
138. Cione E, La Torre C, Cannataro R, Caroleo MC, Plastina P, Gallelli L. Quercetin, epigallocatechin gallate, curcumin, and resveratrol: from dietary sources to human microrna modulation. Molecules. 2019;25:63.
139. Meyer C, Brockmueller A, Ruiz de Porras V, Shakibaei M. Microbiota and resveratrol: how are they linked to osteoporosis? Cells 2024;13:1145.
140. Wang Y, Hong C, Wu Z, et al. Resveratrol in intestinal health and disease: focusing on intestinal barrier. Front Nutr. 2022;9:848400.
141. Lefferts AR, Norman E, Claypool DJ, Kantheti U, Kuhn KA. Cytokine competent gut-joint migratory T cells contribute to inflammation in the joint. Front Immunol. 2022;13:932393.
142. Bono MR, Tejon G, Flores-Santibañez F, Fernandez D, Rosemblatt M, Sauma D. retinoic acid as a modulator of T cell immunity. Nutrients. 2016;8:349.
143. Jiang Q, Yang G, Liu Q, Wang S, Cui D. Function and role of regulatory T cells in rheumatoid arthritis. Front Immunol. 2021;12:626193.
144. Sun H, Kuk W, Rivera-Nieves J, Lopez-Ramirez MA, Eckmann L, Ginsberg MH. β7 Integrin inhibition can increase intestinal inflammation by impairing homing of CD25hi FoxP3+ regulatory T cells. Cell Mol Gastroenterol Hepatol. 2020;9:369-85.
145. Rossi B, Dusi S, Angelini G, et al. Alpha4 beta7 integrin controls Th17 cell trafficking in the spinal cord leptomeninges during experimental autoimmune encephalomyelitis. Front Immunol. 2023;14:1071553.
146. Song B, Guo W, He Y, Yao X, Sun J, Wang S. Targeting immune cell migration as therapy for inflammatory disease: a review. Front Immunol. 2025;16:1650760.
147. Tajik N, Frech M, Schulz O, et al. Targeting Zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun. 2020;11:1995.
148. Veres-Székely A, Szász C, Pap D, Szebeni B, Bokrossy P, Vannay Á. Zonulin as a potential therapeutic target in microbiota-gut-brain axis disorders: encouraging results and emerging questions. Int J Mol Sci. 2023;24:7548.
149. Brandl C, Bucci L, Schett G, Zaiss MM. Crossing the barriers: revisiting the gut feeling in rheumatoid arthritis. Eur J Immunol. 2021;51:798-810.
150. Shan L, Chelliah R, Rahman SME, Hwan Oh D. Unraveling the gut microbiota’s role in Rheumatoid arthritis: dietary pathways to modulation and therapeutic potential. Crit Rev Food Sci Nutr. 2025;65:3291-301.
151. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol. 2016;9:229-39.
152. Arora U, Kedia S, Ahuja V. The practice of fecal microbiota transplantation in inflammatory bowel disease. Intest Res. 2024;22:44-64.
153. Ser HL, Letchumanan V, Goh BH, Wong SH, Lee LH. The use of fecal microbiome transplant in treating human diseases: too early for poop? Front Microbiol 2021;12:519836.
154. Belvoncikova P, Maronek M, Gardlik R. Gut dysbiosis and fecal microbiota transplantation in autoimmune diseases. Int J Mol Sci. 2022;23:10729.
155. Hamamah S, Gheorghita R, Lobiuc A, Sirbu IO, Covasa M. Fecal microbiota transplantation in non-communicable diseases: recent advances and protocols. Front Med (Lausanne). 2022;9:1060581.
156. Kragsnaes MS, Kjeldsen J, Horn HC, et al. Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. Ann Rheum Dis. 2021;80:1158-67.
157. Seida I, Al Shawaf M, Mahroum N. Fecal microbiota transplantation in autoimmune diseases - An extensive paper on a pathogenetic therapy. Autoimmun Rev. 2024;23:103541.
158. Lu C, Chen J, Yi C, et al. Gut microbiota mediated the protective effects of tuna oil on collagen-induced arthritis in mice. Food Funct. 2021;12:5387-98.
159. Profir M, Roşu OA, Creţoiu SM, Gaspar BS. Friend or foe: exploring the relationship between the gut microbiota and the pathogenesis and treatment of digestive cancers. Microorganisms. 2024;12:955.
160. Ivashkin V, Poluektov Y, Kogan E, et al. Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome. PLoS One. 2021;16:e0252930.
161. Bagheri S, Zolghadri S, Stanek A. Beneficial effects of anti-inflammatory diet in modulating gut microbiota and controlling obesity. Nutrients. 2022;14:3985.
162. Luo Y, Tong Y, Wu L, et al. Alteration of gut microbiota in individuals at high-risk for rheumatoid arthritis associated with disturbed metabolome and the initiation of arthritis through the triggering of mucosal immunity imbalance. Arthritis Rheumatol. 2023;75:1736-48.
163. Zeng L, Deng Y, Yang K, Chen J, He Q, Chen H. Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: a systematic review and meta-analysis. Front Immunol. 2022;13:944387.
164. Cold F, Svensson CK, Petersen AM, Hansen LH, Helms M. Long-term safety following faecal microbiota transplantation as a treatment for recurrent Clostridioides difficile infection compared with patients treated with a fixed bacterial mixture: results from a retrospective cohort study. Cells. 2022;11:435.
165. Ooijevaar RE, van Nood E, Goorhuis A, et al. Ten-year follow-up of patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection from a randomized controlled trial and review of the literature. Microorganisms. 2021;9:548.
166. Quaranta G, Guarnaccia A, Fancello G, et al. Fecal microbiota transplantation and other gut microbiota manipulation strategies. Microorganisms. 2022;10:2424.
167. Mitsou EK, Katsagoni CN, Janiszewska K. Knowledge of dietitians on gut microbiota in health-an online survey of the European federation of the associations of dietitians (EFAD). Nutrients. 2024;16:621.
168. Dai Z, Cheng W, Peng H, et al. Microbiota composition-based donor selection affects FMT efficacy in a murine colitis model. Front Immunol. 2025;16:1635244.
169. Haq S, Grondin J, Banskota S, Khan WI. Autophagy: roles in intestinal mucosal homeostasis and inflammation. J Biomed Sci. 2019;26:19.
170. Zhao J, Duan L, Li J, et al. New insights into the interplay between autophagy, gut microbiota and insulin resistance in metabolic syndrome. Biomed Pharmacother. 2024;176:116807.
171. Purdel C, Margină D, Adam-Dima I, Ungurianu A. The beneficial effects of dietary interventions on gut microbiota-an up-to-date critical review and future perspectives. Nutrients. 2023;15:5005.
172. Mitra S, Munni YA, Dash R, et al. Gut microbiota in autophagy regulation: new therapeutic perspective in neurodegeneration. Life (Basel). 2023;13:957.
173. Niechcial A, Schwarzfischer M, Wawrzyniak M, et al. Spermidine ameliorates colitis via induction of anti-inflammatory macrophages and prevention of intestinal dysbiosis. J Crohns Colitis. 2023;17:1489-503.
174. Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16:38-51.
175. Xuan H, Ou A, Hao S, Shi J, Jin X. Galangin protects against symptoms of dextran sodium sulfate-induced acute colitis by activating autophagy and modulating the gut microbiota. Nutrients. 2020;12:347.
176. Fu R, Wang L, Meng Y, et al. Apigenin remodels the gut microbiota to ameliorate ulcerative colitis. Front Nutr. 2022;9:1062961.
177. Ermencheva P, Kotov G, Shumnalieva R, Velikova T, Monov S. Exploring the role of the microbiome in rheumatoid arthritis-a critical review. Microorganisms. 2024;12:1387.
178. Ghosh S, Whitley CS, Haribabu B, Jala VR. Regulation of intestinal barrier function by microbial metabolites. Cell Mol Gastroenterol Hepatol. 2021;11:1463-82.
179. Fu Y, Lyu J, Wang S. The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective. Front Immunol. 2023;14:1277102.
180. Engevik MA, Herrmann B, Ruan W, et al. Bifidobacterium dentium-derived y-glutamylcysteine suppresses ER-mediated goblet cell stress and reduces TNBS-driven colonic inflammation. Gut Microbes. 2021;13:1-21.
181. Jian H, Liu Y, Wang X, Dong X, Zou X. Akkermansia muciniphila as a next-generation probiotic in modulating human metabolic homeostasis and disease progression: a role mediated by gut-liver-brain axes? Int J Mol Sci 2023;24:3900.
182. Wang SL, Shao BZ, Zhao SB, et al. Intestinal autophagy links psychosocial stress with gut microbiota to promote inflammatory bowel disease. Cell Death Dis. 2019;10:391.
183. Ke P, Shao BZ, Xu ZQ, Chen XW, Liu C. Intestinal autophagy and its pharmacological control in inflammatory bowel disease. Front Immunol. 2016;7:695.
184. Lapaquette P, Bizeau JB, Acar N, Bringer MA. Reciprocal interactions between gut microbiota and autophagy. World J Gastroenterol. 2021;27:8283-301.
185. Arab HH, Al-Shorbagy MY, Saad MA. Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways. Chem Biol Interact. 2021;335:109368.
186. Zhang W, Zou M, Fu J, Xu Y, Zhu Y. Autophagy: A potential target for natural products in the treatment of ulcerative colitis. Biomed Pharmacother. 2024;176:116891.
187. Buruiană A, Florian ȘI, Florian AI, et al. The roles of miRNA in glioblastoma tumor cell communication: diplomatic and aggressive negotiations. Int J Mol Sci. 2020;21:1950.
188. Zhang Y, Yang M, Xie H, Hong F, Yang S. Role of miRNAs in rheumatoid arthritis therapy. Cells. 2023;12:1749.
189. Cunningham CC, Wade S, Floudas A, et al. Serum miRNA signature in rheumatoid arthritis and “at-risk individuals”. Front Immunol. 2021;12:633201.
190. Kmiołek T, Paradowska-Gorycka A. miRNAs as biomarkers and possible therapeutic strategies in rheumatoid arthritis. Cells. 2022;11:452.
191. Datta N, Johnson C, Kao D, et al. MicroRNA-based therapeutics for inflammatory disorders of the microbiota-gut-brain axis. Pharmacol Res. 2023;194:106870.
192. Gu L, Ren F, Fang X, Yuan L, Liu G, Wang S. Exosomal MicroRNA-181a derived from mesenchymal stem cells improves gut microbiota composition, barrier function, and inflammatory status in an experimental colitis model. Front Med (Lausanne). 2021;8:660614.
193. Yang F, Ni B, Liu Q, et al. Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota. Stem Cell Res Ther. 2022;13:475.
194. Teng Y, Ren Y, Sayed M, et al. Plant-Derived Exosomal MicroRNAs Shape the Gut Microbiota. Cell Host Microbe. 2018;24:637-652.e8.
195. Nikolaieva N, Sevcikova A, Omelka R, Martiniakova M, Mego M, Ciernikova S. Gut microbiota-microRNA interactions in intestinal homeostasis and cancer development. Microorganisms. 2022;11:107.
196. Díez-Sainz E, Lorente-Cebrián S, Aranaz P, Riezu-Boj JI, Martínez JA, Milagro FI. Potential mechanisms linking food-derived microRNAs, gut microbiota and intestinal barrier functions in the context of nutrition and human health. Front Nutr. 2021;8:586564.
197. Casado-Bedmar M, Viennois E. MicroRNA and gut microbiota: Tiny but mighty-novel insights into their cross-talk in inflammatory bowel disease pathogenesis and therapeutics. J Crohns Colitis. 2022;16:992-1005.
198. Li M, Chen WD, Wang YD. The roles of the gut microbiota-miRNA interaction in the host pathophysiology. Mol Med. 2020;26:101.
199. Turner JE, Stockinger B, Helmby H. IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS Pathog. 2013;9:e1003698.
201. Han H, Davidson LA, Fan YY, et al. Loss of aryl hydrocarbon receptor suppresses the response of colonic epithelial cells to IL22 signaling by upregulating SOCS3. Am J Physiol Gastrointest Liver Physiol. 2022;322:G93-G106.
202. Nehmar R, Fauconnier L, Alves-Filho J, et al. Aryl hydrocarbon receptor (Ahr)-dependent Il-22 expression by type 3 innate lymphoid cells control of acute joint inflammation. J Cell Mol Med. 2021;25:4721-31.
203. Xiao X, Mao X, Chen D, et al. miRNAs Can affect intestinal epithelial barrier in inflammatory bowel disease. Front Immunol. 2022;13:868229.
204. Zhao S, Zhu L, Feng W, et al. MicroRNA-602 prevents the development of inflammatory bowel diseases in a microbiota-dependent manner. Exp Ther Med. 2021;22:1373.
205. Kyoko OO, Kono H, Ishimaru K, et al. Expressions of tight junction proteins Occludin and Claudin-1 are under the circadian control in the mouse large intestine: implications in intestinal permeability and susceptibility to colitis. PLoS One. 2014;9:e98016.
206. Chen Z, Guan D, Wang Z, et al. Microbiota in cancer: molecular mechanisms and therapeutic interventions. MedComm (2020). 2023;4:e417.
207. Zhao Y, Zeng Y, Zeng D, et al. Probiotics and microRNA: their roles in the host-microbe interactions. Front Microbiol. 2020;11:604462.
208. Ionescu RF, Enache RM, Cretoiu SM, Cretoiu D. the interplay between gut microbiota and miRNAs in cardiovascular diseases. Front Cardiovasc Med. 2022;9:856901.
209. Zhao LY, Mei JX, Yu G, et al. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. Signal Transduct Target Ther. 2023;8:201.
210. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024;19:275-93.
211. Shao T, Hsu R, Rafizadeh DL, et al. The gut ecosystem and immune tolerance. J Autoimmun. 2023;141:103114.
212. Dong Y, Yao J, Deng Q, et al. Relationship between gut microbiota and rheumatoid arthritis: a bibliometric analysis. Front Immunol. 2023;14:1131933.
213. Lv X, Wang X, Wang X, et al. Research progress in arthritis treatment with the active components of Herba siegesbeckiae. Biomed Pharmacother. 2023;169:115939.
214. Mitra S, Dash R, Nishan AA, Habiba SU, Moon IS. Brain modulation by the gut microbiota: from disease to therapy. J Adv Res. 2023;53:153-73.
215. Schinzari F, Tesauro M, Cardillo C. Vasodilator dysfunction in human obesity: established and emerging mechanisms. J Cardiovasc Pharmacol. 2021;78:S40-52.
